Pancreatic cancer is among the most lethal solid tumours in India, with roughly 15,000 new cases and a near-equal number of deaths each year according to ICMR National Cancer Registry Programme data, and GLOBOCAN 2022 places the country squarely in the rising-incidence band for both ductal adenocarcinoma and the rarer neuroendocrine subset. The factor that separates a patient headed for a curative Whipple procedure at a tertiary cancer centre from one starting palliative FOLFIRINOX at a tertiary cancer centre is the stage at diagnosis and, just as critically, the NCCN resectability classification assigned at the pancreas-protocol CT. This page explains how pancreatic cancer is staged at leading cancer centres in the region using the AJCC TNM 8th edition, what each subtype means for prognosis and treatment, what every clinical scenario looks like from the patient side, and what Delhi NCR families can expect in terms of diagnostic pathway, treatment options and indicative costs. (See the GLOBOCAN India pancreas fact sheet and the NCI PDQ on pancreatic cancer treatment.)
What Pancreatic Cancer Staging Actually Means
Staging tells the treating team how large the tumour is, whether it has grown into nearby blood vessels or organs, whether it has reached regional lymph nodes, and whether it has spread to distant sites such as the liver, lungs or peritoneum. Across every major hospital in Delhi, Gurgaon and Noida the system used is the American Joint Committee on Cancer Tumour-Node-Metastasis classification, 8th edition (AJCC TNM 8e), published in 2017 and still current in 2026. The 8th edition introduced a size-based T-category system for pancreatic ductal adenocarcinoma, replacing the 7th edition criteria that relied heavily on extension beyond the pancreas. The change was driven by poor inter-observer reproducibility: pathologists frequently disagreed on whether a tumour had extended beyond the pancreatic parenchyma, while measuring maximum tumour diameter proved far more consistent. Stage groups combine the T, N and M descriptors into a single Roman numeral from IA to IV that correlates with expected survival and drives the treatment sequence. (See the UICC TNM resources and Allen et al., AJCC 8e validation, Ann Surg 2017.)
Why AJCC TNM 8e Uses Tumour Size Instead of Extrapancreatic Extension
The shift from extrapancreatic extension in the 7th edition to maximum tumour diameter in the 8th edition was not cosmetic. Multiple large validation studies across resected-patient cohorts in the United States, Europe and Asia confirmed that maximum diameter separated survival curves more cleanly than the old extension-based system. The T descriptors now run as follows. T1 covers tumours two centimetres or smaller in greatest dimension, with sub-categories T1a (up to half a centimetre), T1b (greater than half a centimetre up to one centimetre), and T1c (greater than one centimetre up to two centimetres). T2 covers tumours larger than two centimetres but no more than four centimetres. T3 covers tumours larger than four centimetres. T4 designates a tumour of any size that involves the coeliac axis, the superior mesenteric artery, or the common hepatic artery. The N descriptor was also revised: N0 is no regional lymph node metastasis, N1 is metastasis in one to three regional nodes, and N2 is metastasis in four or more regional nodes. M status remains binary: M0 and M1. In the 8th edition, any tumour with four or more positive nodes is classified as Stage III even if the primary is small and technically resectable, reflecting the strong influence of nodal burden on outcome. (See Kamarajah et al., AJCC 8e SEER validation, Ann Surg Oncol 2017 and Strobel et al., international AJCC 8e validation, JAMA Surg 2018.)
Resectability Classification: The Parallel Decision Framework for Pancreatic Cancer
Beyond the formal TNM stage, clinical decision-making at Delhi NCR hospitals relies on a parallel resectability classification endorsed by the NCCN. This framework divides patients into four categories: resectable (no arterial contact, no or limited venous contact allowing reconstruction), borderline resectable (limited arterial contact with the superior mesenteric artery or coeliac axis, or venous contact with reconstruction feasible), locally advanced unresectable (unreconstructable arterial encasement or venous occlusion), and metastatic. The resectability assessment is performed on a pancreas-protocol contrast-enhanced CT or MRI at the time of diagnosis, and the result shapes the treatment sequence: surgery first versus neoadjuvant therapy versus palliative systemic therapy. Five-year relative survival rates from the United States SEER database (2014 to 2020 diagnoses) illustrate the stage gradient: localised disease carries a five-year relative survival around 44 percent, regional disease around 16 percent, and distant disease around 3 percent. Only about 13 percent of patients are diagnosed while the tumour is still localised. Indian registry data from the ICMR National Cancer Registry Programme show that the age-standardised incidence has been rising over the past two decades, with slightly higher rates in urban populations of western and northern India. (See the NCCN Pancreatic Adenocarcinoma guidelines and NCI SEER Pancreatic Cancer Stat Facts.)
Pancreatic Ductal Adenocarcinoma: The Dominant 85 to 90 Percent Histology
Pancreatic ductal adenocarcinoma (PDAC) is the dominant histology, accounting for roughly 85 to 90 percent of all pancreatic cancers. It arises from the ductal epithelium and is characterised by an intense desmoplastic stroma that contributes to chemoresistance and poor vascularity. PDAC is graded as well, moderately, or poorly differentiated. Molecular profiling identifies four consensus transcriptomic subtypes: classical/progenitor, basal-like/squamous, immunogenic, and aberrantly differentiated endocrine-exocrine, although in clinical practice the distinction that most influences treatment selection is basal-like versus classical, because basal-like tumours respond poorly to FOLFIRINOX. The signature somatic mutations are KRAS (found in over 90 percent), TP53 (roughly 70 percent), CDKN2A (roughly 30 percent), and SMAD4 (roughly 30 percent). Actionable alterations are uncommon but include microsatellite instability-high (MSI-H) in one to two percent, BRCA1/2 somatic mutations in four to seven percent, NTRK fusions under one percent, and NRG1 fusions under one percent. (See the WHO Classification of Digestive System Tumours, 5th edition and Collisson et al., Nat Med 2011, pancreatic cancer subtypes.)
WHO 2019 Variants of Ductal Adenocarcinoma in the Pancreas
The WHO 2019 classification of digestive system tumours recognises several morphologic variants of PDAC, each with distinct behaviour. Adenosquamous carcinoma (one to four percent of cases) carries a worse prognosis than conventional PDAC. Colloid (mucinous non-cystic) carcinoma, often arising from an intraductal papillary mucinous neoplasm (IPMN), has a somewhat more favourable outcome stage for stage. Medullary carcinoma is associated with MSI-H and may respond to immune checkpoint inhibitors, which makes it critical to test for mismatch repair status in this variant. Hepatoid, undifferentiated, undifferentiated with osteoclast-like giant cells, and signet-ring variants are all rare. Acinar cell carcinoma accounts for roughly one to two percent of exocrine pancreatic cancers and can present with a paraneoplastic syndrome of subcutaneous fat necrosis, polyarthralgia, and eosinophilia caused by lipase hypersecretion. Pancreatoblastoma, a rare tumour seen mainly in children under ten, carries a better prognosis than PDAC when fully resected. IPMN with an associated invasive carcinoma is staged and treated as PDAC, while non-invasive IPMNs are not staged but are monitored according to Fukuoka/Kyoto guidelines. Mucinous cystic neoplasm (MCN) with invasion occurs almost exclusively in women and follows the exocrine TNM table. (See Nagtegaal et al., WHO 2019 digestive tumours classification, Histopathology 2020 and the Basturk et al., pancreatic cystic neoplasm consensus, Am J Surg Pathol 2015.)
Pancreatic Neuroendocrine Tumours: WHO Grading, Separate TNM and Functional Syndromes
Pancreatic neuroendocrine tumours (PanNETs) account for three to five percent of all pancreatic neoplasms. They are graded by the WHO 2019 system using mitotic rate and Ki-67 proliferation index: G1 (mitotic rate under 2 per 10 high-power fields, Ki-67 under 3 percent), G2 (mitotic rate 2 to 20, Ki-67 3 to 20 percent), and G3 (mitotic rate above 20, Ki-67 above 20 percent). The distinction between a well-differentiated NET G3 and a poorly differentiated neuroendocrine carcinoma (NEC) is critical because the two behave differently and respond to different therapies: well-differentiated PanNETs often have MEN1, DAXX, or ATRX mutations, while NECs typically harbour TP53 and RB1 alterations. PanNETs are staged using a separate AJCC TNM 8e table: T1 (under 2 cm limited to pancreas), T2 (2 to 4 cm limited to pancreas), T3 (over 4 cm or invading duodenum or common bile duct), T4 (invading adjacent organs or walls of large vessels). SEER data indicate a five-year survival of roughly 93 percent for localised PanNET, 77 percent for regional, and 27 percent for distant, which is substantially better than PDAC at every stage. About 10 to 30 percent of PanNETs secrete hormones that cause recognisable clinical syndromes: insulinomas (hypoglycaemia), gastrinomas (Zollinger-Ellison syndrome), VIPomas (watery diarrhoea), glucagonomas (necrolytic migratory erythema), and somatostatinomas. Solid pseudopapillary neoplasm (SPN), predominantly in young women, is staged using the exocrine TNM system and is usually cured by resection. (See the NCI PDQ on PanNET treatment and Dasari et al., JAMA Oncol 2017, NET incidence and survival trends.)
Painless Obstructive Jaundice: The Classic Pancreatic Cancer Presentation
A tumour in the head of the pancreas, which accounts for roughly 60 to 70 percent of PDAC cases, can compress or infiltrate the intrapancreatic portion of the common bile duct, blocking bile flow. The patient notices yellowing of the eyes and skin, dark urine the colour of tea, and pale or clay-coloured stools. Itching can be intense. On examination, the gallbladder may be palpable and non-tender, a finding known as Courvoisier sign. This is the presentation that most commonly triggers a CT scan and biopsy at leading cancer centres in the region and the other major pancreatic cancer referral centres in Delhi NCR. Painless jaundice in any adult over fifty should prompt urgent cross-sectional imaging rather than empirical treatment for gallstones or drug-induced liver injury. (See the Pancreatic Cancer StatPearls, NLM.)
New-Onset Diabetes, Weight Loss and Back Pain as Pancreatic Cancer Warning Signs
Beyond jaundice, several presentations should raise suspicion for pancreatic cancer across Delhi, Gurgaon and Noida. New-onset diabetes in a person over fifty: roughly half of PDAC patients have diabetes or impaired glucose tolerance at diagnosis, and in some the diabetes appears only six to eighteen months before the cancer is found. A sudden rise in blood sugar in a previously well-controlled diabetic, or new diabetes in a lean older adult with no family history, should prompt a cross-sectional imaging study of the pancreas. Unintentional weight loss, reported by up to 90 percent of patients at diagnosis, results from reduced food intake, malabsorption from pancreatic duct obstruction, and tumour-driven catabolic metabolism. Epigastric or mid-back pain, a deep dull ache that may radiate straight through to the mid-back, worsening after meals or when lying flat and partially relieved by sitting forward, is more common with body and tail tumours where the tumour invades or compresses the coeliac plexus. When pain is the presenting symptom, the tumour is often locally advanced. (See the NCI PDQ on pancreatic cancer diagnosis and Sharma et al., Pancreas 2018, diabetes and pancreatic cancer.)
Acute Pancreatitis, Steatorrhoea, VTE and Depression: Less Obvious Pancreatic Cancer Clues
In a patient over fifty with a first episode of acute pancreatitis and no gallstones, no alcohol history, and no metabolic trigger, a pancreatic tumour should be excluded; the tumour can obstruct the main pancreatic duct and trigger upstream inflammation. Steatorrhoea with bulky, pale, greasy stools that float indicates fat malabsorption from duct obstruction preventing digestive enzymes from reaching the duodenum. Nausea, early satiety and gastric outlet obstruction can develop when a large head-of-pancreas tumour presses on or invades the duodenum. Venous thromboembolism: an unexplained deep vein thrombosis or pulmonary embolism in a person over fifty with no other risk factor is sometimes the first clue, as pancreatic cancer has among the highest rates of paraneoplastic thrombosis of any solid tumour (Trousseau syndrome). Depression and anxiety preceding the diagnosis have been documented in several studies; unexplained mood change in combination with weight loss or vague abdominal discomfort should heighten clinical suspicion. For PanNETs the presentation can differ: functional tumours produce hormone-driven symptoms such as recurrent hypoglycaemia, severe peptic ulcers, profuse watery diarrhoea, or a characteristic skin rash with diabetes. Non-functional PanNETs grow silently and present late with mass effect, pain, or incidental detection on imaging. (See Risch, PMC 4560741, pancreatic cancer precursor lesions.)
Tobacco, Diabetes and Obesity: Modifiable Risk Factors for Pancreatic Cancer in India
Cigarette smoking is the most clearly established modifiable risk factor, responsible for roughly 20 to 25 percent of pancreatic cancers globally. The risk is dose-dependent: heavy smokers carry roughly a two-fold increase compared with non-smokers, and the risk remains elevated for about ten years after quitting. Bidi smoking, which delivers higher tar and nicotine per stick than many manufactured cigarettes, is common across north India and carries a comparable or greater risk. Smokeless tobacco products (gutka, khaini, zarda) have been associated with pancreatic cancer in Indian case-control studies. Type 2 diabetes mellitus has a bidirectional relationship: long-standing diabetes (duration greater than five years) roughly doubles the odds of developing PDAC, while new-onset diabetes can be the earliest metabolic sign of an existing tumour. In India, where the diabetes prevalence exceeds 11 percent of the adult population, this connection has growing clinical relevance. Obesity with a BMI of 30 or above increases pancreatic cancer risk by roughly 20 to 40 percent, with central adiposity potentially mattering more than BMI alone, and with urban India experiencing rapid increases in overweight this risk factor is becoming more significant in the Delhi NCR context. (See Klein, Nat Rev Gastroenterol Hepatol 2021, pancreatic cancer epidemiology and ICMR-NCDIR National Cancer Registry Programme.)
Chronic Pancreatitis, Hereditary Syndromes and Family History in Pancreatic Cancer
Patients with chronic pancreatitis carry a roughly 13 to 16-fold increased risk of pancreatic cancer over the general population. The risk is highest in tropical pancreatitis, a form seen in southern and parts of eastern India, and in hereditary pancreatitis caused by PRSS1 mutations, where the cumulative lifetime risk approaches 40 percent by age 70 in some series. Heavy alcohol intake (roughly three or more drinks per day) is a risk factor largely mediated through its role in causing chronic pancreatitis. Between five and ten percent of pancreatic cancers have a familial or hereditary basis: BRCA2 is the single most common high-penetrance gene, found in roughly six to 19 percent of familial pancreatic cancer kindreds. Other genes include BRCA1, PALB2, ATM, CDKN2A (carriers have a 12 to 38-fold increased risk), STK11 (Peutz-Jeghers syndrome, lifetime pancreatic cancer risk 11 to 36 percent), and the mismatch repair genes MLH1, MSH2, MSH6, and PMS2 (Lynch syndrome). Having one first-degree relative with pancreatic cancer roughly doubles the risk; two or more affected relatives raise it six to 12-fold. The NCCN recommends germline genetic testing for all patients diagnosed with pancreatic cancer because the result can influence therapy. No single risk factor explains most cases; the median age at diagnosis in India is between 55 and 65, about five to ten years younger than in Western populations. (See Raimondi et al., pancreatic cancer in chronic pancreatitis, Best Pract Res Clin Gastroenterol 2010 and Petersen, familial pancreatic cancer, Semin Oncol 2016.)
Blood Markers and Pancreas-Protocol CT: Starting the Pancreatic Cancer Diagnostic Workup
The diagnostic pathway for pancreatic cancer in Delhi, Gurgaon and Noida typically begins when a patient presents with painless jaundice, unexplained weight loss, or new-onset diabetes after age fifty. Serum CA 19-9 is the most widely used tumour marker, elevated (above 37 U/mL) in roughly 80 percent of PDAC patients, but it is not specific: obstructive jaundice from any cause, pancreatitis, cholangitis and other gastrointestinal cancers can also raise it. Roughly five to ten percent of the population are Lewis antigen negative and cannot produce CA 19-9 at all, so a normal level does not exclude cancer. Liver function tests, a complete blood count, renal function panel, and fasting glucose round out the baseline bloodwork. The single most important imaging study is a pancreas-protocol contrast-enhanced CT: thin-slice multidetector CT with an arterial phase (timed at roughly 40 seconds) and a portal venous phase (roughly 70 seconds). The arterial phase highlights the relationship between the tumour and the coeliac axis, superior mesenteric artery, and common hepatic artery. The portal venous phase shows the portal vein, superior mesenteric vein, and hepatic parenchyma. Sensitivity for detecting a primary pancreatic mass exceeds 90 percent when the protocol is followed correctly. A standard abdomen CT without pancreas-specific timing can miss small tumours and underestimate vascular involvement. (See Goonetilleke and Siriwardena, CA 19-9 review, Eur J Surg Oncol 2007 and Al-Hawary et al., SAR/APA pancreatic radiology reporting template, Radiology 2014.)
EUS-FNA, MRI and PET-CT in Pancreatic Cancer Tissue Acquisition and Staging
MRI with MRCP is typically a second-line problem-solving tool, superior to CT for characterising small liver lesions, for evaluating the pancreatic duct and biliary anatomy, and for patients who cannot receive iodinated CT contrast. For cystic pancreatic lesions (IPMN, MCN), MRI is the preferred modality for surveillance and characterisation. Endoscopic ultrasound with fine-needle aspiration or biopsy (EUS-FNA/FNB) is the most sensitive modality for detecting small tumours under two centimetres that may be occult on CT, and achieves a sensitivity of roughly 85 to 95 percent and specificity above 95 percent for confirming malignancy. The tissue obtained is used for histopathological diagnosis and molecular profiling including KRAS, microsatellite instability, BRCA status and NTRK fusions. EUS-guided biopsy is preferred over percutaneous CT-guided biopsy because the needle track remains within the surgical field, reducing the risk of peritoneal seeding. FDG PET-CT is not part of the routine initial workup for all patients but is useful for detecting occult distant metastases in borderline resectable or locally advanced disease and for evaluating equivocal CT findings. For PanNETs, Gallium-68 DOTATATE PET-CT, which targets somatostatin receptors, is the preferred functional imaging study and is available at a tertiary cancer centre, a leading cancer centre Gurgaon, and a tertiary cancer centre. (See Hewitt et al., EUS-FNA meta-analysis, Gastrointest Endosc 2012 and Hope et al., somatostatin receptor PET appropriate use criteria, J Nucl Med 2018.)
Staging Laparoscopy and Germline Testing: Completing the Pancreatic Cancer Workup
Before committing a patient to a Whipple procedure, some centres perform a staging laparoscopy: a short procedure under general anaesthesia in which a camera is inserted into the abdomen to look for liver surface metastases, peritoneal deposits, and positive peritoneal cytology. CT misses occult peritoneal or liver surface disease in roughly 15 to 30 percent of patients initially deemed resectable. The NCCN considers staging laparoscopy optional for resectable disease but recommends it when CA 19-9 is markedly elevated, when the primary is in the body or tail, when the tumour is borderline resectable, or when imaging findings are equivocal. If peritoneal cytology is positive, the disease is classified as M1 and the patient is spared an unnecessary laparotomy. Germline genetic testing is recommended for all patients diagnosed with pancreatic cancer, regardless of family history or stage. The panel typically includes BRCA1, BRCA2, PALB2, ATM, CDKN2A, STK11, and mismatch repair genes. Somatic (tumour-tissue) profiling through next-generation sequencing identifies actionable targets such as MSI-H, NTRK fusions, NRG1 fusions, KRAS G12C mutations, and tumour mutational burden. All results are discussed in a multidisciplinary tumour board that includes a hepatopancreatobiliary surgical oncologist, medical oncologist, radiation oncologist, radiologist with pancreatic expertise, pathologist and gastroenterologist. (See Fong et al., staging laparoscopy yield, Ann Surg Oncol 2023 and the NCCN Pancreatic Adenocarcinoma guidelines, germline testing section.)
Clinical Versus Pathological Staging in Pancreatic Cancer Reports
Once the diagnostic workup is complete, the treating team assigns a clinical stage (cTNM) using imaging and biopsy results. After surgery, the pathologist assigns a pathological stage (pTNM) based on examination of the resected specimen, which is generally more accurate. Clinical T category is based on tumour size measured on imaging, though CT can underestimate size by up to 20 percent. Clinical N category is estimated from lymph node size, morphology and FDG avidity, but imaging has limited sensitivity for nodal metastases smaller than one centimetre. After pancreatoduodenectomy or distal pancreatectomy, the pathologist measures the tumour, counts the number of examined and positive lymph nodes (the 8th edition requires at least 12 for accurate N staging), assesses margin status (R0 if margins are clear, R1 if microscopic tumour is present at a margin), and looks for lymphovascular and perineural invasion. Tumour regression grading scores the proportion of residual viable tumour cells to fibrosis in patients who received neoadjuvant therapy. The College of American Pathologists synoptic reporting template is used at most Delhi NCR centres. For PanNETs, the workup includes Gallium-68 DOTATATE PET-CT, 24-hour urine 5-HIAA if a functional syndrome is suspected, and serum chromogranin A. The Ki-67 proliferation index determines the WHO grade, which is reported alongside the TNM stage and is critical for treatment selection. (See the CAP synoptic reporting templates and Tsai et al., CA 19-9 normalization after neoadjuvant therapy, Ann Surg 2020.)
Resectability Classification in the Radiology and Tumour Board Report
Alongside the TNM stage, the radiology or tumour board report at leading cancer centres in the region will state whether the tumour is resectable, borderline resectable, locally advanced, or metastatic. Resectable means no arterial contact and either no venous contact or limited venous abutment allowing safe reconstruction. Borderline resectable means limited arterial abutment (usually up to 180 degrees) or venous involvement that is technically reconstructable but carries higher surgical risk. Locally advanced means the tumour encases the arteries beyond reconstruction or occludes the veins without a technical option for replacement. This classification drives whether the patient goes to surgery, receives neoadjuvant chemotherapy first, or proceeds to systemic treatment only. Patients who receive neoadjuvant therapy are restaged after three to six months with a repeat pancreas-protocol CT, CA 19-9 and sometimes PET-CT. Imaging response criteria (RECIST 1.1) are used, but pancreatic cancer is notorious for having a desmoplastic stroma that does not shrink proportionally even when viable tumour cells have been killed. A decline in CA 19-9 of more than 50 percent during neoadjuvant therapy is a favourable prognostic marker independent of imaging response. (See the NCCN resectability criteria for pancreatic adenocarcinoma and Tempero et al., JNCCN 2021 pancreatic adenocarcinoma guidelines.)
Resectable Pancreatic Cancer: Whipple Procedure and Adjuvant mFOLFIRINOX
Head-of-pancreas tumours are treated with pancreatoduodenectomy, commonly called the Whipple procedure, which removes the head of the pancreas, the duodenum, the distal common bile duct, the gallbladder, and a small portion of the stomach (classical Whipple) or preserves the pylorus (pylorus-preserving variant). Body and tail tumours are treated with distal pancreatectomy, usually with splenectomy. Total pancreatectomy is reserved for multifocal disease or a positive surgical margin at the neck transection. The Whipple procedure is performed at high volume by hepatopancreatobiliary surgical teams at leading cancer centres in the region Saket, a leading cancer centre Gurgaon, a leading cancer centre, and a leading cancer centre. Operative mortality at experienced centres is two to five percent, but morbidity (pancreatic fistula, delayed gastric emptying, post-pancreatectomy haemorrhage) occurs in 30 to 50 percent. Robotic Whipple procedures are performed at leading cancer and tertiary centres, though open surgery remains the standard for most head tumours. After R0 or R1 resection, six months of adjuvant chemotherapy is the standard of care. The PRODIGE-24 trial established modified FOLFIRINOX as the preferred regimen for patients with ECOG 0-1 performance status, with median disease-free survival of 21.6 months versus 12.8 months for gemcitabine alone and median overall survival of 54.4 months versus 34.8 months. (See Conroy et al., PRODIGE-24, NEJM 2018 and Asbun et al., Miami guidelines on minimally invasive pancreas resection, Ann Surg 2020.)
Adjuvant Alternatives and Neoadjuvant Chemotherapy for Resectable PDAC
For patients who cannot tolerate mFOLFIRINOX (older age, borderline performance status, significant comorbidities), gemcitabine plus capecitabine is an evidence-based alternative, supported by the ESPAC-4 trial which showed a median survival of 28.0 months versus 25.5 months for gemcitabine alone. Single-agent gemcitabine remains an option for patients with ECOG 2 performance status. Adjuvant therapy should ideally begin within eight to twelve weeks of surgery. Although surgery-first followed by adjuvant chemotherapy has been the historical standard, there is growing evidence and practice shift toward neoadjuvant chemotherapy even for clearly resectable tumours. The ESPAC-5F trial demonstrated that short-course neoadjuvant chemotherapy led to superior one-year survival compared with immediate surgery in patients with borderline resectable disease, and several single-arm and registry studies have shown benefit in the resectable setting. NCCN guidelines now list neoadjuvant therapy as an option for resectable PDAC, particularly when high-risk features are present: markedly elevated CA 19-9, large primary, regional lymphadenopathy on imaging, significant weight loss, or extreme pain. The typical neoadjuvant regimen is mFOLFIRINOX or gemcitabine plus nab-paclitaxel for two to four months, followed by restaging and surgery. (See Neoptolemos et al., ESPAC-4, Lancet 2017 and Ghaneh et al., ESPAC-5F, Lancet Gastroenterol Hepatol 2023.)
Borderline Resectable Pancreatic Cancer: Neoadjuvant Therapy Before Surgery
Neoadjuvant systemic therapy before surgery is the standard approach for borderline resectable disease. The aim is to downstage the tumour and sterilise microscopic distant disease before attempting resection. The two most commonly used regimens are mFOLFIRINOX and gemcitabine plus nab-paclitaxel (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2, days 1, 8, 15 of a 28-day cycle). Several phase II trials and retrospective series report R0 resection rates of 60 to 80 percent after neoadjuvant therapy. Following four to six months of systemic therapy, patients are restaged with pancreas-protocol CT and CA 19-9. Those without progression proceed to surgery, sometimes with the addition of short-course chemoradiation before the operation. Patients who progress during neoadjuvant therapy are spared a futile operation. After resection, additional adjuvant chemotherapy is given to complete a total perioperative treatment duration of roughly six months. In Delhi NCR, the hepatopancreatobiliary tumour boards at leading cancer centres in the region all follow this neoadjuvant-first pathway for borderline resectable cases. (See the NCCN borderline resectable pancreatic cancer algorithm and Sohal et al., SWOG S1505, JAMA Oncol 2021.)
Locally Advanced Unresectable Pancreatic Cancer: Systemic Therapy and Radiation
Locally advanced unresectable patients have tumours that encase major arteries or occlude veins beyond reconstructive options. First-line systemic chemotherapy mirrors metastatic protocols: FOLFIRINOX or mFOLFIRINOX for fit patients (ECOG 0-1), gemcitabine plus nab-paclitaxel for moderate fitness. NALIRIFOX (liposomal irinotecan, fluorouracil, leucovorin, and oxaliplatin) demonstrated a median overall survival of 11.1 months versus 9.2 months for gemcitabine plus nab-paclitaxel in the NAPOLI-3 trial and is now included in the NCCN guidelines as a first-line option. Treatment continues for four to six months before reassessment. The role of radiation remains debated: the LAP07 trial showed no overall survival difference between continued chemotherapy and chemoradiation after induction, though the chemoradiation arm showed better local control (local progression 32 percent versus 46 percent). Stereotactic body radiation therapy (SBRT), typically delivered in three to five fractions, has emerged as an alternative with one-year local control rates of 70 to 80 percent. MRI-guided adaptive SBRT with dose escalation has shown improved two-year survival in retrospective analyses. SBRT is available at leading cancer centres in the region. A small proportion of patients (roughly 10 to 20 percent) who respond well to neoadjuvant therapy can be reclassified as resectable after restaging. (See Wainberg et al., NAPOLI-3, Lancet 2023 and Hammel et al., LAP07, JAMA 2016.)
Metastatic Pancreatic Cancer: FOLFIRINOX, Gemcitabine-Nab-Paclitaxel and NALIRIFOX
The goal of treatment in stage IV pancreatic cancer is prolongation of survival and maintenance of quality of life. For patients with ECOG 0-1 performance status, the three standard first-line regimens are mFOLFIRINOX, gemcitabine plus nab-paclitaxel, and NALIRIFOX. The PRODIGE-4/ACCORD-11 trial established FOLFIRINOX as superior to gemcitabine alone with median overall survival of 11.1 months versus 6.8 months. The MPACT trial showed gemcitabine plus nab-paclitaxel achieved median overall survival of 8.5 months versus 6.7 months for gemcitabine alone. NALIRIFOX, tested in the NAPOLI-3 trial, demonstrated median overall survival of 11.1 months versus 9.2 months for gemcitabine plus nab-paclitaxel. The modified FOLFIRINOX regimen (reduced irinotecan dose, omission of bolus fluorouracil) is widely preferred in practice because it has a more tolerable toxicity profile. For ECOG 2 patients, single-agent gemcitabine or gemcitabine-based doublets with dose reductions are used. Second-line therapy for patients who progress on gemcitabine-based first-line therapy includes nano-liposomal irinotecan plus fluorouracil and leucovorin as established by the NAPOLI-1 trial, which showed median overall survival of 6.1 months versus 4.2 months for fluorouracil/leucovorin alone. (See Conroy et al., PRODIGE-4/ACCORD-11, NEJM 2011 and Von Hoff et al., MPACT, NEJM 2013.)
Olaparib Maintenance for BRCA-Mutated Metastatic Pancreatic Cancer
For the subset of patients with a germline BRCA1 or BRCA2 mutation (roughly four to seven percent of all PDAC) whose disease has not progressed during at least 16 weeks of first-line platinum-based chemotherapy, olaparib (300 mg twice daily) is an option for maintenance therapy. The phase III POLO trial demonstrated that olaparib maintenance extended progression-free survival compared with placebo (median 7.4 months versus 3.8 months; hazard ratio 0.53). Overall survival did not reach a statistically meaningful difference (median 19.0 months versus 19.2 months), likely confounded by crossover and subsequent therapies, but the time to first and second subsequent therapy both favoured olaparib with clear statistical margins. Olaparib maintenance is available at major centres in Delhi NCR and is covered under some insurance schemes. The NCCN lists it as a category 1 recommendation in this specific population. Immunotherapy in pancreatic cancer is largely ineffective because of low tumour mutational burden and an immunosuppressive microenvironment, with the established exception being MSI-H or mismatch repair-deficient tumours (one to two percent of PDAC). Pembrolizumab (200 mg every three weeks) is approved tissue-agnostically for MSI-H/dMMR solid tumours and can produce durable responses in this small subset. For microsatellite-stable PDAC, single-agent checkpoint inhibitors have not shown benefit. (See Golan et al., POLO trial, NEJM 2019 and Marabelle et al., KEYNOTE-158 MSI-H, J Clin Oncol 2020.)
Targeted Therapies for Rare Pancreatic Cancer Molecular Alterations
NTRK fusion-positive tumours (under one percent of PDAC) respond to larotrectinib (100 mg twice daily) or entrectinib (600 mg once daily), both approved as tissue-agnostic therapies. KRAS G12C mutations (one to two percent of PDAC) can be targeted with sotorasib or adagrasib, which are approved for non-small cell lung cancer and are being studied in pancreatic cancer through the CodeBreaK 100 trial. NRG1 fusions are targetable with zenocutuzumab, under investigation in the eNRGy trial. These scenarios are uncommon but reinforce the case for molecular profiling of every patient at diagnosis. The POLAR trial tested pembrolizumab plus olaparib as maintenance in metastatic PDAC and reported a six-month progression-free survival rate of 64 percent in the overall cohort, but the primary endpoint was not met, and this combination remains investigational. All molecular-driven treatment decisions at leading cancer centres in the region are made through next-generation sequencing panels with results reviewed in the multidisciplinary tumour board. (See Drilon et al., larotrectinib in TRK fusion-positive cancers, NEJM 2018 and Reiss et al., POLAR trial, J Clin Oncol 2025.)
PanNET Treatment: Surgery, Somatostatin Analogues, Everolimus and Sunitinib
Treatment of pancreatic neuroendocrine tumours follows a separate framework from PDAC. Localised PanNETs are treated with resection whenever feasible; small (under two centimetres), non-functional, well-differentiated G1 tumours may be observed with serial imaging. Operations are the same as for PDAC: Whipple for head lesions, distal pancreatectomy for body/tail lesions, and enucleation for small superficial tumours away from the main duct. Cytoreductive surgery of liver metastases is considered for refractory hormone-related symptoms. Octreotide LAR and lanreotide autogel are the backbone of systemic therapy for well-differentiated G1 and G2 PanNETs expressing somatostatin receptors: the CLARINET trial showed lanreotide extended progression-free survival with a hazard ratio of 0.47. Two oral targeted agents are approved for progressive well-differentiated PanNETs: everolimus (RADIANT-3 trial, median PFS 11.0 versus 4.6 months for placebo) and sunitinib (median PFS 11.4 versus 5.5 months for placebo). Both are available at major centres in Delhi NCR. (See the NCI PDQ on PanNET treatment and Caplin et al., CLARINET, NEJM 2014.)
177Lu-DOTATATE PRRT and CAPTEM Chemotherapy for Pancreatic Neuroendocrine Tumours
Lutetium-177 DOTATATE (177Lu-DOTATATE) is a radioligand that binds to somatostatin receptors on tumour cells and delivers targeted beta radiation. The phase III NETTER-1 trial in midgut NETs demonstrated median progression-free survival of 28.4 months versus 8.5 months for high-dose octreotide, and retrospective series plus the ongoing NETTER-2 trial support its use in progressive PanNETs with strong somatostatin receptor expression. PRRT is administered as four cycles of 7.4 GBq each, eight weeks apart, and is available at a tertiary cancer centre nuclear medicine department, a tertiary cancer centre, and a leading cancer centre Gurgaon. Well-differentiated PanNETs also respond to temozolomide-based regimens: the combination of capecitabine plus temozolomide (CAPTEM) is widely used with objective response rates of 30 to 70 percent and median PFS of 14 to 23 months. This regimen is oral, well tolerated and widely prescribed at Delhi NCR centres. For poorly differentiated neuroendocrine carcinomas (NEC, G3 with TP53/RB1 mutations), treatment follows small cell lung cancer protocols: platinum plus etoposide, with response rates of 30 to 60 percent but short duration of response. (See Strosberg et al., NETTER-1, NEJM 2017 and Strosberg et al., CAPTEM in pancreatic endocrine carcinomas, Cancer 2011.)
Palliative Interventions: Biliary Drainage, Duodenal Stenting and Pain Management in Pancreatic Cancer
Patients with obstructive jaundice who are not proceeding to immediate surgery require biliary decompression via ERCP with placement of a self-expanding metal stent, which remains patent longer (median four to six months) than plastic stents (two to three months). Gastric outlet obstruction occurs in 15 to 25 percent of patients with locally advanced or metastatic head-of-pancreas tumours: endoscopic duodenal stenting provides rapid symptom relief, while surgical gastrojejunostomy offers more durable relief for patients with adequate performance status. Pancreatic enzyme supplements (pancreatin or pancrelipase capsules with meals and snacks) are essential for patients with steatorrhoea from duct obstruction or after resection; inadequate enzyme replacement leads to malnutrition, weight loss and fat-soluble vitamin deficiency that undermine tolerance of chemotherapy. Pancreatic cancer pain from coeliac plexus invasion can be severe. The WHO analgesic ladder is the starting framework, and for refractory pain, EUS-guided coeliac plexus neurolysis (injection of absolute alcohol into the coeliac plexus under endoscopic ultrasound guidance) provides meaningful relief in roughly 70 to 80 percent of patients. This procedure is available at all major GI endoscopy centres in Delhi NCR. (See the NCCN pancreatic cancer supportive care guidelines.)
Cost of Pancreatic Cancer Care Across Delhi, Gurgaon and Noida
The figures below are approximate ranges gathered from published hospital rate cards, CGHS and PMJAY package lists, and practitioner estimates across the Delhi National Capital Region as of early 2026. Actual out-of-pocket costs depend on the hospital tier, specific surgeon or oncologist, insurance coverage, room category and whether complications extend the stay. A pancreas-protocol CT abdomen costs roughly INR 4,000 to 10,000 per scan. PET-CT (FDG, whole body) runs INR 12,000 to 25,000, while Gallium-68 DOTATATE PET-CT for PanNETs costs INR 18,000 to 35,000. EUS-guided fine needle aspiration with on-site cytology ranges from INR 15,000 to 35,000. An open Whipple procedure including ICU and 10 to 14 day stay costs roughly INR 3,50,000 to 8,00,000 at private centres, with government tariffs significantly lower. Distal pancreatectomy with splenectomy runs INR 2,50,000 to 5,50,000. ERCP with metal biliary stent placement costs INR 40,000 to 1,20,000 depending on stent type. Neoadjuvant or adjuvant mFOLFIRINOX per cycle costs INR 15,000 to 30,000 for 12 cycles typical. Gemcitabine plus nab-paclitaxel per cycle ranges from INR 25,000 to 60,000. Olaparib maintenance costs INR 35,000 to 80,000 per month for germline BRCA-mutated patients. Pembrolizumab (MSI-H only) costs INR 1,20,000 to 1,80,000 per three-week cycle. 177Lu-DOTATATE PRRT runs INR 1,00,000 to 2,00,000 per cycle for four cycles. Palliative radiation (short-course, 5 fractions) costs INR 50,000 to 1,50,000. EUS-guided coeliac plexus neurolysis costs INR 20,000 to 50,000. Monthly supportive care (enzymes, pain medication, nutrition supplements) runs INR 3,000 to 10,000. PMJAY covers surgical oncology packages including the Whipple procedure at empanelled hospitals, and CGHS and ECHS beneficiaries can access treatment with co-payment structures that vary by room entitlement. Pharmaceutical patient-assistance programmes exist for nab-paclitaxel, olaparib, pembrolizumab and larotrectinib. (See the PMJAY hospital empanelment portal and the a tertiary cancer centre Evidence Based Management, pancreas chapter.)
Pancreatic Cancer FAQs for NCR Patients and Families
What does resectable versus borderline resectable versus locally advanced mean? These terms describe how much the pancreatic tumour involves nearby blood vessels. Resectable means the surgeon can remove the tumour with clear margins and reconstruct any affected veins. Borderline resectable means the tumour touches key arteries or veins in a way that makes surgery possible but technically difficult, so chemotherapy is given first to shrink it. Locally advanced means the tumour wraps around major arteries too extensively for safe removal, and systemic therapy becomes the primary treatment. Why is my doctor recommending chemotherapy before pancreatic surgery? Neoadjuvant chemotherapy treats potential micrometastases early, tests whether the tumour biology responds to treatment, and improves the odds of achieving negative surgical margins; the PRODIGE-24 and ESPAC-5 trials inform this approach. What is the difference between FOLFIRINOX and gemcitabine plus nab-paclitaxel for pancreatic cancer? FOLFIRINOX tends to produce higher response rates and longer survival in fit patients but carries more side effects, particularly diarrhoea, neutropenia and neuropathy; gemcitabine plus nab-paclitaxel is tolerated better in patients with moderate performance status. The modified FOLFIRINOX schedule used in practice reduces the irinotecan dose and omits bolus fluorouracil. How long does recovery from a Whipple procedure take? Most patients spend 7 to 14 days in hospital; full recovery takes two to three months; pancreatic enzyme supplements start before discharge and continue indefinitely. Is immunotherapy effective in pancreatic cancer? For the vast majority with microsatellite-stable PDAC, current checkpoint inhibitors have not demonstrated meaningful benefit; the clear exception is the one to two percent with MSI-H/dMMR tumours, where pembrolizumab can produce durable responses. What is olaparib maintenance and who qualifies? Olaparib is a PARP inhibitor for patients with metastatic PDAC carrying a germline BRCA1/2 mutation whose disease has not progressed after at least 16 weeks of platinum-based chemotherapy; the POLO trial showed it roughly doubled the time before progression. Can pancreatic neuroendocrine tumours be cured? When caught at stage I or II and fully resected, well-differentiated PanNETs have five-year survival rates exceeding 80 percent, and even in the metastatic setting they respond to somatostatin analogues, targeted drugs and PRRT. Where in Delhi NCR can I get a Whipple procedure? High-volume pancreatic surgery is performed at leading cancer centres in the region Saket and Patparganj, a leading cancer centre Gurgaon, a leading cancer centre, a leading cancer centre, and a leading cancer centre; hospitals performing more than 20 to 25 Whipple procedures per year consistently report lower complication rates. Is PRRT available in Delhi NCR for neuroendocrine tumours? Yes, at the nuclear medicine departments of leading cancer centres Gurgaon and several other centres; four cycles are given eight weeks apart. How often will I need scans during and after pancreatic cancer treatment? During chemotherapy, restaging CT or MRI is done every two to three months; after curative-intent surgery and adjuvant chemotherapy, surveillance includes CT and CA 19-9 every three to six months for the first two years, then every six to twelve months to year five. What dietary changes are needed after pancreatic surgery? Lifelong pancreatic enzyme replacement capsules with every meal, five to six smaller meals instead of three large ones, moderate fat initially but not eliminated, and dietitian consultation before discharge. What palliative care options exist for pancreatic cancer? Palliative care should begin alongside active treatment and includes pain management via the WHO ladder and coeliac plexus neurolysis, nutritional support with enzyme supplements, biliary drainage for jaundice, duodenal stenting for gastric outlet obstruction, and home-based programmes such as CanSupport in Delhi. Can a family member be at risk if I have a germline BRCA mutation? Yes, first-degree relatives have a 50 percent chance of carrying the same mutation, raising lifetime risk for breast, ovarian, prostate and pancreatic cancers; genetic counselling for the family is recommended at leading cancer centres in the region cancer genetics clinics. (See the NCCN Genetic/Familial High-Risk Assessment guidelines and the NCI PDQ on pancreatic cancer treatment and follow-up.)
Overview
Treatment Options